Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC).

被引：0
|
作者：
Khawaja, M. R.
Younger, A.
Funke, J. M.
Waddell, M. J.
Jones, D. R.
Pollok, K.
Prasad, N. K.
Berry, W.
Sandusky, G.
Chiorean, E. G.
机构：
[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[2] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS157
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
    Whorf, R. C.
    Hainsworth, J. D.
    Spigel, D. R.
    Yardley, D. A.
    Burris, H. A., III
    Waterhouse, D. M.
    Vazquez, E. R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    BLOOD, 2009, 114 (22) : 1481 - 1481
  • [43] Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer.
    Wolpin, Brian M.
    Ng, Kimmie
    Zhu, Andrew X.
    Abrams, Thomas Adam
    Enzinger, Peter C.
    McCleary, Nadine
    Meyerhardt, Jeffrey A.
    Schrag, Deborah
    Kwak, Eunice Lee
    Allen, Jill N.
    Bhargava, Pankaj
    Chan, Jennifer A.
    Goessling, Wolfram
    Blaszkowsky, Lawrence Scott
    Elliott, Meaghan
    Shellock, Maria
    Regan, Eileen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [44] DRAFT: RAMSETE trial of everolimus (RAD001) in the treatment of silent (nonfunctioning) advanced neuroendocrine tumors
    Wiedenmann, B.
    Caglio, S.
    Decroix, L.
    May, C.
    Oberg, K. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced Hematologic malignancies
    Yee, K
    O'Brien, S
    Wierda, W
    Thomas, D
    Kurzrock, R
    Fayad, L
    Hagemeister, F
    Goy, A
    Cortes, J
    Prestifilippo, J
    Szatrowski, T
    Kantarjian, H
    Giles, F
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : S35 - S35
  • [46] Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    Kroog, G. S.
    Feldman, D. R.
    Kondagunta, G. V.
    Ginsberg, M. S.
    Fischer, P. M.
    Trinos, M. J.
    Patil, S.
    Ishill, N. M.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: Results of a phase I trial
    Azria, David
    Rebillard, Xavier
    Coux, Nathalie
    Jarlier, Marta
    Thuret, Rodolphe
    Llacer-Moscardo, Carmen
    Charissoux, Marie
    Culine, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [48] Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC)
    Kotsakis, A. P.
    Tarhini, A.
    Petro, D.
    Flaugh, R.
    Vallabhaneni, G.
    Belani, C. P.
    Friedland, D.
    Argiris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC)
    Owonikoko, T. K.
    Stoller, R. G.
    Petro, D.
    Flaugh, R.
    Hershberger, P. A.
    Belani, C. P.
    Argiris, A. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC)
    Kotsakis, Athanasios
    Tarhini, Ahmad
    Petro, Daniel
    Flaugh, Rick
    Vallabhaneni, Geetha
    Belani, Chandra
    Friedland, David
    Argiris, Athanassios
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S464 - S464
12345